UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden
hours per response:
0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue.
See
Instruction 1(b).
1. Name and Address of Reporting Person*YOUNG JOHN D
(Last)
(First)
(Middle)
PFIZER INC.-CORP. SECRETARY
235 EAST 42ND ST.
(Street)
NEW YORK
NY
10017
(City)
(State)
(Zip)
2. Issuer Name and Ticker or Trading Symbol
PFIZER INC
[ PFE ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director
10% Owner
Officer (give title below)
Other (specify below)
Group President
3. Date of Earliest Transaction
(Month/Day/Year)
12/29/2017
4. If Amendment, Date of Original Filed
(Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr.
3)
2. Transaction Date
(Month/Day/Year)
2A. Deemed Execution Date, if any
(Month/Day/Year)
3. Transaction Code (Instr.
8)
4. Securities Acquired (A) or Disposed Of (D) (Instr.
3, 4 and 5)
5.
Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr.
3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr.
4)
7. Nature of Indirect Beneficial Ownership (Instr.
4)
Code
Amount
(A) or (D)
Price
Common Stock
12/29/2017
55,218(1)
$0.0000
179,700
Common Stock
1,592
By Rule 16b-3 Plan
Common Stock
1,410
By Trustee under the Pfizer Share Ownership Plan
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr.
3)
2. Conversion or Exercise Price of Derivative Security
3. Transaction Date
(Month/Day/Year)
3A. Deemed Execution Date, if any
(Month/Day/Year)
4. Transaction Code (Instr.
8)
5.
Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr.
3, 4 and 5)
6. Date Exercisable and Expiration Date
(Month/Day/Year)
7. Title and Amount of Securities Underlying Derivative Security (Instr.
3 and 4)
8. Price of Derivative Security (Instr.
5)
9.
Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr.
4)
10. Ownership Form: Direct (D) or Indirect (I) (Instr.
4)
11. Nature of Indirect Beneficial Ownership (Instr.
4)
Code
(A)
(D)
Date Exercisable
Expiration Date
Title
Amount or Number of Shares
Phantom Stock Units SSP
(2)
12/29/2017
11
(3)
(3)
Common Stock
11
$36.22
8,966
Stock Appreciation Rights
$36.22
12/29/2017
343,053
12/29/2022(4)
12/29/2022(4)
Common Stock
343,053
$0.0000
343,053
Explanation of Responses:
1. The reported transaction constitutes the grant of restricted stock units which will vest one third on each of the second, third and fourth anniversaries of grant provided he is continuously employed by Pfizer through the respective anniversaries.
2. Each unit represents one phantom share of common stock.
3. These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.
4. The stock appreciation rights will settle on the fifth anniversary of the grant date (December 29, 2022) subject to both of the following requirements being met: (a) the reporting person remains continuously employed by Pfizer through the third anniversary of the grant date (December 29, 2020) and (b) Pfizer's total shareholder return is at least 25% or higher on average for 30 consecutive trading days anytime within the five-year performance period (which ends on December 29, 2022).
Susan E. Grant, by power of atty., for John D. Young
01/03/2018
** Signature of Reporting Person
Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person,
see
Instruction
(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations
See
18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient,
see
Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.